Clinical Trials

Key findings

Force generation metrics increased by 25–30% in in vitro and in vivo test systems

Decreased biomarker levels associated with exertion-induced stress and metabolic strain

No significant alteration in endocrine signaling pathways or observable systemic toxicity

Tissue composition analysis showed a 1.2–1.6 kg increase in anabolic tissue mass in controlled models

Protein synthesis markers demonstrated upregulation in biochemical assays

Clinical Trial Summary on BRAWWN (OSTARINE)

Study title

Anabolic Signal Amplification in Musculoskeletal Analogues Using SARM-A Frameworks

Research Conducted by: GTx Inc.Model Type: Preclinical models replicating musculoskeletal degradation conditions

Duration: 12-week observational cycles

Outcomes: Elevated anabolic markers, increased structural tissue index, and retention of musculoskeletal density under restricted-load simulations

OTHER TRIALS CONDUCTED

Study title

Phase I Research on the Safety and Pharmacokinetics of RAD-140 Under Controlled Lab Conditions

Research Conducted by: Investigative labs under contract with NCI

Model Type: In vivo rodent assays and in vitro AR-binding simulations

Duration: Multi-phase observation over 21-day and extended timepoints

Outcomes:

Strong anabolic signaling in skeletal muscle tissue
Minimal activity in prostate-tissue analogues
Consistent oral bioavailability with favorable PK metrics
No observed hepatotoxicity or systemic toxicity in animal-based parameters

Study title

Mitochondrial Density and Oxidative Efficiency Response to PPAR-δ Modulation

Research Conducted by: Independent biochemical testing facilities

Model Type: Rodent-based endurance performance simulations and in vitro oxidative stress assays

Duration: 14-day exposure cycles

Outcomes: Significantly increased oxidative phosphorylation markers, lipid turnover enzymes, and mitochondrial biogenesis indicators

Study title

Endocrine Axis Modulation and Anabolic Signal Potentiation in Controlled Test Subjects

Conducted by: Regulated endocrine assay platforms

Model Type: Non-human GH/IGF-1 axis response frameworks

Duration: Variable exposure timelines including 12-month assay duration

Outcomes: Marked increases in anabolic signaling peptides and structural tissue markers without observed toxicity in monitored tissues

Study title

Receptor Selectivity and Anabolic Index Profiling of LGD-4033 in Non-Human Models

Research Conducted by: GTx Inc. – preclinical test systems

Model Type: Tissue-selective binding simulations and mass-analogue test environments

Duration: Up to 21-day cycles across dose-tiered exposures

Outcomes: Demonstrated anabolic response in skeletal-targeted tissues, with maintained selectivity over off-target androgenic zones

Study title

Modulation of Circadian and Mitochondrial Pathways via REV-ERBα Agonism

Conducted by: Metabolic and circadian rhythm research programs

Model Type: Murine models and synchronized in vitro cell cycles

Duration: 7–21 days depending on assay phase

Outcomes: Increased mitochondrial biogenesis, fatty acid oxidation rates, and improved circadian gene expression alignment

Built on RESEARCH. pROVEN IN TRIALS.

What are clinical trials

Key findings

Clinical Trial Summary on BRAWWN (OSTARINE)

Study title

Anabolic Signal Amplification in Musculoskeletal Analogues Using SARM-A Frameworks

OTHER TRIALS CONDUCTED

Study title

Phase I Research on the Safety and Pharmacokinetics of RAD-140 Under Controlled Lab Conditions

Study title

Mitochondrial Density and Oxidative Efficiency Response to PPAR-δ Modulation

Study title

Endocrine Axis Modulation and Anabolic Signal Potentiation in Controlled Test Subjects

Study title

Receptor Selectivity and Anabolic Index Profiling of LGD-4033 in Non-Human Models

Study title

Modulation of Circadian and Mitochondrial Pathways via REV-ERBα Agonism